top of page

Novel Alzheimer's Drug Slows Cognitive Decline in Phase 2 Trial

Results from a phase 2 placebo-controlled trial of the investigational antiamyloid drug donanemab show that the novel agent met the primary outcome of slowing cognitive decline in patients with early symptomatic Alzheimer's disease (AD).

Results from the TRAILBLAZER-ALZ trial were presented at the 2021 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) and were simultaneously published online March 13 in the New England Journal of Medicine.

As previously reported by Medscape Medical News, topline results showed that donanemab slowed cognitive decline by 32% on the Integrated AD Rating Scale (iADRS) from baseline to 76 weeks relative to placebo.

The newly released detailed findings showed that "the use of donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed," the investigators, with first author Mark A. Mintun, MD, an employee of Eli Lilly, report.

Read more here :

1 view0 comments

Recent Posts

See All


bottom of page